AIDS treatment and diagnostics abroad

AIDS, or acquired immunodeficiency syndrome, is the most advanced stage of HIV infection. Severe damage to the immune system increases vulnerability to certain infections and cancers. Diagnosis depends on established clinical and laboratory criteria, not appearance or a positive HIV test alone. Persistent fever, unexplained weight loss, prolonged diarrhoea or new breathing or neurological symptoms need medical assessment, but symptoms by themselves cannot establish AIDS. People may first present with advanced disease or return to care after a treatment interruption.

Care focuses on urgent assessment of complications, effective antiretroviral therapy (ART) and support to remain in treatment. An experienced HIV team selects investigations and preventive medicines according to immune function, symptoms, exposure and local infection risks. Active opportunistic infections may change the timing or choice of HIV therapy. Effective treatment can support immune recovery but does not cure HIV. Anyone with serious or rapidly worsening symptoms should seek local urgent care before considering travel.

What advanced HIV care involves

AIDS describes advanced HIV infection with severe immune damage or particular AIDS-defining illnesses. A positive HIV test alone does not establish this stage. CD4 cell counts help assess immune function, while viral load measures HIV activity. Clinicians also assess current illness, previous treatment, medication access and other health conditions.

Persistent fever, weight loss, cough, diarrhoea or difficulty swallowing need prompt investigation. Some complications can initially produce few symptoms. The assessment may include testing for tuberculosis, cryptococcal disease or other opportunistic infections, chosen according to CD4 count, symptoms, geography and clinical guidance. A single identical panel is not appropriate for everyone.

Treating HIV and its complications

ART remains central to care and should be planned promptly by an experienced team. However, the safest timing depends on any active infection. Certain central nervous system infections, including cryptococcal meningitis, require treatment and a planned delay before starting ART. Starting or changing medicines without specialist advice can cause harmful interactions or complications.

Each opportunistic infection needs its own treatment. Some people also need medicines to prevent a first infection or recurrence; eligibility and stopping decisions depend on immune recovery and other factors. New or worsening inflammation after ART starts may reflect immune reconstitution, but other causes must be assessed. Do not assume that deterioration is an expected treatment effect.

Support includes nutrition, symptom relief, mental health, practical help obtaining medicines and a clear follow-up plan. Pregnancy and childhood require specific expertise, including different assessment criteria and dosing. Effective ART can improve immune function, although recovery and treatment risks vary.

Urgent care and follow-up

Severe breathlessness, confusion, seizures, a new severe headache, sudden visual changes or inability to keep fluids down needs urgent local care. Do not wait for travel or a scheduled remote consultation. Following stabilisation, arrange continuity of ART, infection treatment, laboratory monitoring and preventive care with the receiving team.

Frequently asked questions

Is AIDS a different virus from HIV?

No. AIDS is a stage of illness caused by HIV-related immune damage. HIV infection can be present without AIDS.

Can treatment still help after an AIDS diagnosis?

Yes. ART and treatment of complications remain important and can allow immune recovery. HIV is not cured, and ongoing care is necessary.

Should ART always start on the day of assessment?

Prompt treatment is important, but some active infections require a different sequence. The HIV team determines timing after assessment.

Can preventive infection medicines replace ART?

No. They address selected infection risks and do not control HIV itself. Their use must be reviewed alongside ART and immune monitoring.